First Efficacy Results Of A Randomized, Open-Label, Phase Iii Study Of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed By Docetaxel With Or Without Capecitabine, In High-Risk Early Breast Cancer

CANCER RESEARCH(2010)

引用 30|浏览38
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要